First Human Trial of Bundibugyo Ebola Vaccine Begins as Death Toll Tops 700

For healthcare system leaders and policymakers, the launch of this trial tests whether the global vaccine infrastructure built during COVID-19 can be repurposed for an ongoing filovirus emergency, even as overtaxed clinics and public health agencies in the DRC and Uganda struggle to contain the outbreak.

The first-ever human clinical trial of a vaccine targeting the Bundibugyo strain of Ebola has begun, marking a significant milestone in the fight against a deadly outbreak that has already claimed more than 700 lives in central Africa. The early-stage trial, which will enroll 50 healthy adults, is designed to evaluate the vaccine’s safety and immune response. Developed with funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and led by researchers at the University of Oxford, the vaccine leverages a proven chimpanzee adenovirus vector platform—the same technology underpinning the Oxford-AstraZeneca COVID-19 shot. The Serum Institute of India, the world’s largest vaccine manufacturer by volume, has already produced and stockpiled about 620,000 doses in anticipation of later-stage trials and potential emergency use, with 4,000 doses supplied for this initial study.

“

Jean Kaseya, Director-General of the Africa Centres for Disease Control and Prevention, cautioned that the trial is “not an immediate solution for communities facing the outbreak today” but is vital for building future resilience.

The urgency is acute. The World Health Organization (WHO) declared the Bundibugyo Ebola outbreak, which spans the Democratic Republic of Congo (DRC) and neighboring Uganda, a Public Health Emergency of International Concern (PHEIC) 57 days before the trial launched. This designation, which accelerates research and funding, reflects the severity of an epidemic that has overwhelmed local health systems. Unlike the Zaire Ebola strain, for which licensed vaccines exist, there are no approved vaccines or specific treatments for Bundibugyo, leaving responders without a countermeasure they can deploy. The new vaccine, officially designated ChAdOx1-biEBOV, represents a crucial step toward closing that gap.

The trial’s initiation demonstrates how pandemic-era advances have compressed vaccine development timelines. The use of a versatile adenovirus platform allowed rapid antigen design, and CEPI’s proactive funding model enabled parallel manufacturing—a strategy that has evolved from the COVID-19 pandemic. The Serum Institute’s decision to stockpile 620,000 doses before any clinical data is a high-risk, high-reward move that could shave months off deployment if the vaccine proves effective. However, early-stage trials are notoriously slow to generate efficacy evidence, and the current outbreak may well burn out before a vaccine can be validated. Dr. Jean Kaseya, Director-General of the Africa Centres for Disease Control and Prevention, cautioned that the trial is “not an immediate solution for communities facing the outbreak today” but is vital for building future resilience.

From a manufacturing and regulatory perspective, the trial faces additional hurdles. Even if safety data is encouraging, larger efficacy trials in an outbreak setting are logistically complex. The Bundibugyo virus has historically appeared less frequently than Zaire, making case accrual for a Phase 3 study difficult. Furthermore, any emergency use authorization would likely rely on immunogenicity bridging data and perhaps animal rule approval, a pathway that regulators are still refining for filovirus vaccines. The stockpiled doses could be deployed under an expanded access protocol if the situation deteriorates, but that would require cooperation with national health authorities and the World Health Organization.